HealthDay: 'Neuroprotectant' drug could boost outcomes after stroke
UC's Broderick comments on study
A new study found using a "neuroprotectant" drug alongside the standard surgical removal of a blood clot may reduce the risk of death and disability following a stroke.
Researchers presenting data at the International Stroke Conference reported the medication, called ApTOLL, protects brain tissue from continuing damage by cooling down inflammation.
More than 150 people who had an ischemic stroke were enrolled in the study in France and Spain, either receiving ApTOLL at two different doses or a placebo medication in addition to mechanical blood clot removal.
The patients who received the higher dose of ApTOLL were four times less likely to die from stroke compared to the patients who received a placebo.
Joseph Broderick, MD, professor in UC’s Department of Neurology and Rehabilitation Medicine in the College of Medicine, director of the UC Gardner Neuroscience Institute and a UC Health physician, commented on the study for HealthDay. He said the drug needs to be tested more thoroughly before becoming a standard of care.
"The data warrants further study in a phase 3 study, but differences seen in this trial may be due to small number of patients and imbalances in factors related to outcome," Broderick said, adding that a much larger trial would be needed to confirm the findings.
Featured photo at top of Dr. Broderick. Photo/Joseph Fuqua II/University of Cincinnati
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.